Wegovy HD Coverage · Verified April 21, 2026
Wegovy HD Prior Authorization: What Actually Gets Approved in 2026
Last reviewed:
Sources: FDA-approved Wegovy prescribing information; NovoCare live coverage checker; Novo Nordisk PA Quick Reference and Exceptions/Denials/Appeals Guide; CVS Caremark public Wegovy criteria (CF_RxCriteria_WEGOVY_4774-C); HCSC/Prime Weight Management Program Summary; Highmark public Wegovy PA form; UHC Commercial Plans public PA policy (effective 2/1/2026); Oregon Prescription Drug List; CMS Medicare GLP-1 Bridge FAQ (March 2026); Ro weight-loss pricing and insurance pages; Novo Nordisk press releases (FDA approval March 19, 2026; nationwide availability April 7, 2026).
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
The short version — and it’s not what you expected
Wegovy HD prior authorization is usually harder than regular Wegovy approval — not because the medicine works differently, but because the 7.2 mg dose only launched nationwide on April 7, 2026, and most payer systems are still catching up. Even if your plan covered Wegovy 2.4 mg without a fight, it may not yet recognize the HD pen (NDC 0169-4572-14). NovoCare’s live coverage checker currently returns “no insurance coverage available for Wegovy injection 7.2 mg” for most plan lookups. At the same time, Oregon’s public drug list already lists “WEGOVY HD PEN INJCTR” as pharmacy-PA, and HCSC/Prime’s public summary explicitly names the 7.2 mg dose. Coverage is fragmented right now. The real question isn’t “Does my plan cover Wegovy?” It’s “Does my plan recognize this dose, under this indication, this week?”
NDC to know: Wegovy HD pen = 0169-4572-14. Your pharmacy needs this number if the claim bounces.
Self-pay fallback: NovoCare Pharmacy self-pay is $399/month for HD (vs. $349/month for Wegovy 2.4 mg). Novo Nordisk commercial savings card: as little as $25/month when covered.
Medicare update: Medicare GLP-1 Bridge covers Wegovy HD starting July 1, 2026 at $50/month for eligible Part D beneficiaries.
Ro’s GLP-1 Insurance Coverage Checker calls your plan directly and sends a personalized report with your coverage status and PA requirements. Commercial and FEHB plans only.
Figure out your lane before you do anything else
Before you call your insurance or contact your doctor again, figure out which of these four situations you’re in. The right next move is completely different depending on your lane.
This is the majority of the traffic to this page. Your fastest path is a free coverage check to see whether your plan has loaded the HD NDC yet, then either a clean step-up PA from your prescriber or a concierge service that handles it for you.
Jump to the commercial path →Commercial telehealth concierges (including Ro) generally cannot handle GLP-1 coverage for government plans. But Medicare is changing in your favor on July 1, 2026, with the Medicare GLP-1 Bridge. Skip the commercial sections entirely.
Jump to the Medicare section →A cleaner PA packet won’t fix a benefit exclusion. You’re in exception-request, letter-of-medical-necessity, or self-pay territory — and potentially employer-benefits escalation.
Jump to denials and exclusions →HD isn’t your lane yet. Per the FDA label, standard Wegovy starts at 0.25 mg once weekly and titrates up over about 16 weeks. You need to complete titration and tolerate 2.4 mg for at least 4 weeks before a 7.2 mg step-up.
See our full Wegovy telehealth comparison →The Wegovy HD coverage reality matrix
Why Wegovy HD prior authorization is different from regular Wegovy approval: the 7.2 mg pen has its own NDC. Wegovy coverage and Wegovy HD coverage are not the same problem. Some payers have loaded HD. Most haven’t updated their public policy documents yet. The FDA label adds a step-up requirement that didn’t exist for 2.4 mg.
Last verified April 21, 2026. Re-verified monthly. Sources linked in each row.
| Source / system | Lists Wegovy HD? | What it says | What that means for you |
|---|---|---|---|
| FDA prescribing information | Yes | Adults on Wegovy for weight reduction who tolerate 2.4 mg for at least 4 weeks and still need more weight reduction may increase to a maximum of 7.2 mg once weekly. | If your PA request doesn't show 4+ weeks on 2.4 mg, your insurer can deny on clinical grounds. |
| NovoCare live coverage checker | Yes | Currently displays "no insurance coverage available for Wegovy injection 7.2 mg" for most plan lookups. HD self-pay listed at $399/month. | Strongest single proof that payer systems are still loading the HD NDC. |
| HCSC / Prime Therapeutics public program summary | Yes | Lists Wegovy HD explicitly; quantity limit 4 pens per 28 days; requires baseline BMI, documented diet/activity/behavior changes, current therapy evidence. | Some payers are already loaded. If you're HCSC/Prime, you're in better shape than most. |
| Oregon Prescription Drug List | Yes | Shows "WEGOVY HD PEN INJCTR" as a pharmacy prior-auth drug. | Public state formularies are acknowledging HD — this isn't theoretical. |
| CMS Medicare GLP-1 Bridge (July 1–Dec 31, 2026) | Yes, by NDC | Central-processor PA for Wegovy (injection and tablets) and Zepbound for weight loss. CMS's published NDC list includes 0169-4572-14 for Wegovy HD. | Medicare beneficiaries have a specific July 1, 2026 path — don't miss it. |
| CVS Caremark public Wegovy criteria | No explicit HD language | Generic Wegovy rules: BMI ≥30 or ≥27 with weight-related comorbidity; 6 months of a comprehensive weight-management program; continuation requires ≥5% weight loss after 3 months on stable maintenance dose. | Largest PBM's public PA file doesn't name HD yet. Doesn't mean denial — call the pharmacy help desk with NDC 0169-4572-14 to confirm the claim routes correctly. |
| Highmark public Wegovy PA form | No explicit HD language | Standard Wegovy form; heavy lifestyle-modification documentation requirements (chart notes, subscription receipts, dietary logs, gym records, counseling). | "I did the program" isn't enough. Your plan wants paper. |
| UnitedHealthcare Commercial Plans public policy (effective 2/1/2026) | No | Public commercial file is for CV risk reduction and MASH indications only. States that weight-loss drugs are typically a benefit exclusion. | If you're UHC commercial and chasing HD for weight loss, you may be fighting an exclusion, not a documentation gap. Confirm with member services before spending time on a PA packet. |
| Ro public weight-loss pages | Not by HD name yet | Lists Wegovy pen and Wegovy pill; insurance concierge offered for commercial and FEHB plans; Ro Body $39 first month, $149/month ongoing, or as low as $74/month annual. | Best-in-class commercial helper for this query. Confirm 7.2 mg dispensing during the free coverage check before committing. |
Don’t want to chase this down yourself? Ro’s free GLP-1 Insurance Coverage Checker contacts your insurer directly and sends a personalized report with your Wegovy coverage status, whether PA is required, and your estimated copay.
Check your Wegovy HD coverage free with Ro →Ro’s insurance specialists call your plan and email you a personalized report. Takes about 5 minutes. Commercial and FEHB plans only.
Who Wegovy HD is actually for — and who it’s not
Wegovy HD 7.2 mg is an adult weight-reduction dose only, and only after tolerating Wegovy 2.4 mg for at least 4 weeks. Per the FDA-approved prescribing information, the 7.2 mg dose is for adults using Wegovy for weight reduction who have tolerated the 2.4 mg maintenance dose for 4 weeks or longer and still need additional weight reduction. It is not a starter dose. It is not currently labeled for cardiovascular risk reduction at the 7.2 mg level.
If you’re brand new to Wegovy
You don’t start on HD. Standard Wegovy injection titration begins at 0.25 mg once weekly and steps up roughly every 4 weeks (0.25 → 0.5 → 1 → 1.7 → 2.4 mg) to the 2.4 mg maintenance dose. Only after tolerating 2.4 mg for at least 4 weeks does HD become an option.
If you’re on Wegovy for cardiovascular risk reduction
The 2.4 mg dose is what’s established for that use. HD is specifically a weight-reduction step-up, not a CV step-up. A PA written under the CV indication for 7.2 mg will likely be denied on clinical grounds.
If your BMI and clinical picture don’t fit the criteria
HD may not be the right ask at all. BMI ≥30, or ≥27 with a weight-related condition like type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Another medication might fit better.
If you’ve tolerated Wegovy 2.4 mg for 4+ weeks and still need weight reduction
You’re exactly who HD is for, per the FDA label. This is the population that most payers will approve, once the documentation is complete and the NDC is loaded.
The exact PA packet your doctor needs for Wegovy HD
An incomplete packet is the single most common reason a Wegovy PA gets denied — not ineligibility. Clean the packet, and approval odds climb. Here’s what every major payer asks for, compiled from the Novo Nordisk PA Quick Reference Guide and public payer forms from CVS Caremark, Highmark, HCSC/Prime, and others.
Baseline BMI within the last 30 days
Dated vitals from a recent office visit, not a self-report. The BMI calculation should be clearly shown on the chart note.
Qualifying condition documentation
BMI ≥30 alone, or BMI ≥27 plus at least one weight-related condition documented with an ICD-10 code.
| ICD-10 | Description |
|---|---|
| E66.01 | Morbid (severe) obesity due to excess calories |
| E66.811–E66.813 | Obesity class 1, 2, or 3 |
| I10 | Hypertension |
| E11.x | Type 2 diabetes |
| E78.x | Dyslipidemia |
| G47.33 | Obstructive sleep apnea |
| I25.x | Established cardiovascular disease |
Documented lifestyle modification program
Most payers ask for at least 6 months of structured diet, physical activity, and behavioral modification. Highmark’s public form lists acceptable documentation: chart notes, subscription receipts (WW, Noom), dietary logs, gym records, and counseling notes. “I tried to eat better” is not enough. Bring receipts.
Prior weight-loss medication trials
Phentermine, Contrave, Qsymia, orlistat, or another GLP-1. Document dates, doses, duration, outcome, and reason for discontinuation. If you had intolerable side effects or contraindications, note that — it can satisfy step therapy. Prior Ozempic use (same active ingredient, semaglutide) often counts.
Current and historical Wegovy dose history — the HD-specific line item
This is the item most patients miss. Your medical record must clearly show at least 4 consecutive weeks of tolerated Wegovy 2.4 mg before a 7.2 mg step-up request. That’s the FDA label requirement. No workarounds. If the fill history isn’t in the chart, get the pharmacy printout.
Clinical rationale for stepping up to HD
"Additional weight reduction is clinically indicated." In practice: weight loss plateau at 2.4 mg, BMI still above target, ongoing comorbidities, or documented inadequate response after a reasonable period on the maintenance dose.
Safety screening documented
No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No prior serious hypersensitivity to semaglutide. Not currently using another GLP-1 receptor agonist. Not pregnant or planning pregnancy.
Renewal criteria (6 or 12 months out)
- \u2713≥5% body weight loss from your baseline, or maintenance of initial 5% loss
- \u2713Documentation of continued lifestyle program participation
- \u2713Confirmation you’re still at your maintenance dose
- \u2713No new contraindications
Printable packet builder
Fill in what you know. Leave what you don’t. Hand it to your prescriber’s office — it cuts the back-and-forth.
Member info:
- Insurer / PBM: ________________
- Plan name / group number: ________________
- Member ID: ________________
Clinical:
- Current BMI: _______ (measured within last 30 days: Yes / No)
- Baseline BMI before starting Wegovy: _______
- Qualifying condition(s) + ICD-10 code(s): ________________
- Date started Wegovy titration: _______
- Date reached Wegovy 2.4 mg: _______
- Weeks tolerated at Wegovy 2.4 mg: _______ (must be \u22654 for HD)
- Weight loss from baseline: _______ lbs / _______ %
- Reason HD is clinically indicated: plateau on 2.4 mg / ongoing comorbidity / weight still above target / other: ________________
Lifestyle program documentation available:
- ☐ Chart notes (dates: _______)
- ☐ Dietary logs or food tracking records
- ☐ Gym or fitness program records
- ☐ Counseling or behavioral health notes
- ☐ Subscription receipts (WW, Noom, etc.)
Ask your prescriber to request:
- ☐ The appropriate Wegovy HD PA form from the insurer’s provider portal
- ☐ Letter of Medical Necessity (Novo template US25SEMO01618 as starting point)
- ☐ That the claim specifies NDC 0169-4572-14 for the HD pen if a bounce happens
For a deeper dive on writing a strong letter of medical necessity, see our GLP-1 letter of medical necessity guide.
Wegovy HD prior authorization by plan
Each entry below links to the current public policy document where available. If your plan isn’t named here, call the pharmacy help desk on the back of your card and ask two specific questions: “Is Wegovy HD loaded in your system under NDC 0169-4572-14?” and “What are your prior authorization criteria for a dose step-up from Wegovy 2.4 mg to Wegovy HD 7.2 mg?”
CVS Caremark
Preferred GLP-1As of July 2025, CVS Caremark moved Wegovy to preferred status on its largest commercial formularies and removed Zepbound from preferred. If your plan's PBM is Caremark, Wegovy is typically the preferred GLP-1 and step therapy is generally not required. The current public Wegovy criteria still reflect generic Wegovy rules — the public PDF doesn't yet name HD specifically. Your step-up PA may need a manual nudge if the claim bounces, but being on Caremark is the best-case scenario for Wegovy coverage today.
UnitedHealthcare (Commercial)
Read the fine printUHC's public 2026 commercial policy for Wegovy is explicitly titled "Cardiovascular Risk Reduction and MASH Only" — meaning the public policy exists for those two indications, and notes that weight-loss drugs are typically a benefit exclusion on many UHC commercial plans. If your UHC plan has an obesity drug benefit, your PA runs through that benefit (confirm with member services). If not, a cleaner PA won't fix it. For the CV indication: age 45+, established cardiovascular disease, BMI ≥27, and concurrent diet and physical activity.
HCSC / Prime Therapeutics (BCBS of IL, TX, NM, OK, MT)
HD explicitly listedPublicly loaded Wegovy HD. Prime's Weight Management Program Summary explicitly lists Wegovy HD, with a quantity limit of 4 pens per 28 days, and requires baseline BMI, documented diet/activity/behavior changes, and current therapy or renewal evidence. This is among the cleanest paths to HD coverage we've verified.
Highmark
HD not yet namedHighmark's public Wegovy PA form doesn't yet explicitly name HD. The form is heavy on lifestyle-modification documentation requirements — and it helpfully lists what counts: chart notes, subscription receipts, dietary logs, gym records, and counseling notes.
Oregon Health Plan (Medicaid)
HD already listedAlready lists "WEGOVY HD PEN INJCTR" on the public drug list as pharmacy-PA. A useful precedent to cite if you're on a state plan that says HD isn't loaded yet.
Other major plans (Aetna, Anthem / BCBS, Cigna, Express Scripts, Humana, Kaiser)
Each of these plans covers Wegovy 2.4 mg with prior authorization on their current formularies. None of their public 2026 PA policy documents explicitly name Wegovy HD as of our April verification. That is not the same as “denied” — it means the public policy file hasn’t been revised yet.
In practice, your best move is to call the pharmacy help desk number on the back of your card and ask the two questions above. We’ll publish plan-specific rows in this matrix as each payer publishes Wegovy HD language.
Why was regular Wegovy approved but Wegovy HD denied?
This is the question that brings most people to this page. Your 2.4 mg coverage came through. The new script came back as denied or not covered. It feels wrong. In most cases, it’s one of five specific problems — and four of them are fixable.
Your plan hasn’t loaded the Wegovy HD NDC yet
Every strength of Wegovy has its own National Drug Code. The HD pen NDC is 0169-4572-14. If your pharmacy benefit manager's claims system hasn't loaded that NDC yet, the claim will reject even though your PA for Wegovy is technically active.
The fix: Your doctor or pharmacy calls the plan's pharmacy help desk and specifically requests the HD NDC be loaded. Provide the NDC directly (your pharmacist has it on the claim rejection). This is an operational update, not an appeal, and many plans resolve it in a few business days.
Your plan wants a new PA for the higher dose
Some plans treat HD as a new-drug PA, others as a dose-escalation PA (faster, lighter paperwork). If your denial reads "authorization required" or "not authorized at this dose," this is your situation.
The fix: Your prescriber submits a dose-escalation PA or a new Wegovy PA with the full packet above. The submission must show 4+ weeks of tolerated 2.4 mg — without that, the FDA-label basis for HD isn't established.
The submission was framed under the wrong indication
Wegovy has four approved indication lanes: adult weight reduction, adult cardiovascular risk reduction, pediatric weight reduction (ages 12+), and adult noncirrhotic MASH. HD is a weight-reduction step-up only. If the PA got submitted under a CV or MASH indication, the reviewer may deny on clinical grounds before anyone looks at whether you'd otherwise qualify.
The fix: Confirm with your prescriber that the PA is written for adult weight reduction, with the correct ICD-10 codes (E66.01, E66.811–813, or similar) and the correct clinical rationale.
Your plan excludes weight-loss drugs entirely
If your employer plan has a benefit exclusion for weight-loss medications — still common on smaller self-funded plans — a Wegovy HD PA submitted under the weight-reduction indication will be denied as a benefit exclusion, full stop.
Three real paths forward:
- •Cardiovascular lane (if clinically appropriate): If you have established cardiovascular disease and meet the CV indication criteria, Wegovy 2.4 mg has a separate FDA-approved indication for CV risk reduction that many plans cover even when they exclude weight-loss drugs. HD specifically is not labeled for CV risk reduction.
- •Employer benefits escalation: Novo Nordisk publishes a free letter template for patients with employer-sponsored insurance to submit to their HR or benefits manager. Combined with your physician’s letter, this moves the conversation to your employer’s benefits committee, where plan design is actually decided.
- •Self-pay fallback: NovoCare Pharmacy self-pay for Wegovy HD is $399/month, compared with $349/month for Wegovy 2.4 mg.
Incomplete documentation
Missing BMI. Missing comorbidity codes. No lifestyle-program evidence. No prior-medication trials. No clear clinical rationale for HD. These denials come back as "criteria not met" or "additional information required."
The fix: Resubmission with the complete packet from the section above.
What to do if your Wegovy HD prior authorization was denied
You have four moves, in order. Get the denial reason in writing first — always. Your legal right. The Explanation of Benefits or denial letter must state the specific reason. Don’t take a verbal “it’s not covered” as the final word.
Get the denial reason in writing
Call the number on the back of your card if you don’t have it in writing yet. The specific denial code tells you which of the five reasons above you’re fighting — and what the right move is.
Fix the root cause and resubmit
If the denial is operational (NDC not loaded) or documentation (packet incomplete), a clean resubmission often beats a formal appeal for speed. Many plans decide a corrected resubmission in days rather than weeks.
Internal appeal + peer-to-peer review
If the denial is clinical (“not medically necessary”) or categorical (“not on formulary”), file an internal appeal. Under federal rules for most non-grandfathered health plans, you generally have 180 days from the date on the denial notice to file. A peer-to-peer review — where your prescriber gets on the phone with the insurer’s medical director — often resolves appeals that look borderline on paper.
External review
If the internal appeal fails, request an independent external review. For most non-grandfathered plans under federal rules, the window is typically 4 months from the final internal denial. An independent medical reviewer — not employed by your plan — looks at your case. Your state insurance commissioner’s office can walk you through it for free.
Free written resources from Novo Nordisk
- •Sample Letter of Medical Necessity (document US25SEMO01618) — for the initial PA or formulary exception
- •Sample Letter of Appeal (document US25SEMO01619) — for post-denial submissions
- •Letter for patients with employer-sponsored insurance — submittable to HR or benefits manager
Most denials are paper denials, not true ineligibility. A complete resubmission that matches your plan’s criteria line-by-line resolves a substantial share of them before any formal appeal is needed.
For a full appeal playbook, see our Wegovy denial appeal guide.
Medicare and Wegovy HD in 2026
For most of 2026, standard Medicare Part D does not cover Wegovy HD for weight loss — but that changes on July 1, 2026. Starting then, a temporary CMS demonstration program called the Medicare GLP-1 Bridge will cover Wegovy (including the HD NDC 0169-4572-14) for weight loss at a $50 flat monthly copay for eligible Medicare Part D beneficiaries. The Bridge runs through December 31, 2026, and serves as the transition to the longer-term BALANCE Model launching in Medicare Part D January 1, 2027.
Medicare GLP-1 Bridge: key details for Wegovy HD
| Detail | What it means |
|---|---|
| Duration | July 1, 2026 through December 31, 2026 |
| Your cost | $50 per monthly supply. Manufacturers provide drugs at net $245/month. |
| Does the $50 count toward your OOP cap? | No. The Bridge runs outside Part D. The $50 doesn’t count toward your deductible, true OOP, or the $2,100 Part D cap. |
| Eligible plans | Standalone Part D (PDP) or MA-PD (HMO, HMOPOS, PPO). SNPs, employer/union group waiver plans, and LI NET included. Private fee-for-service and cost contract plans excluded unless separately enrolled in a PDP. |
| How PA works | Your prescriber submits to a CMS central processor (BIN 028918, PCN MEDDGLP1BR) — not to your Part D plan. Operational details being finalized Spring 2026. |
Bridge clinical eligibility (provider must attest all apply):
- •Adult (≥18), prescribed for weight reduction and maintenance in combination with lifestyle modification, consistent with the FDA-approved label, AND
- •BMI ≥35 at initiation of GLP-1 therapy, OR
- •BMI ≥30 at initiation with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension (SBP >140 or DBP >90 on ≥2 antihypertensives), or CKD stage 3a or above, OR
- •BMI ≥27 at initiation with prediabetes (per ADA guidelines), prior MI, prior stroke, or symptomatic peripheral artery disease.
The cardiovascular lane (available today, not tied to the Bridge)
If you have established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral arterial disease) and BMI ≥27, Wegovy 2.4 mg has a separate FDA-approved indication for CV risk reduction that standard Medicare Part D can cover today through your Part D plan’s normal PA process. Note: Wegovy HD specifically is not labeled for CV risk reduction at the 7.2 mg level. The CV indication is for the 2.4 mg dose. Medicare CV-lane coverage typically keeps you on 2.4 mg, not HD.
After the Bridge: why fall 2026 open enrollment matters
The Bridge ends December 31, 2026. Starting January 1, 2027, the BALANCE Model takes over — but only for Part D plans that voluntarily participate. If your current plan doesn’t opt into BALANCE, you’d need to switch during fall 2026 open enrollment (October 15 – December 7, 2026) to a plan that did.
Practical move: during 2026 open enrollment, ask any prospective Part D plan: “Is this plan participating in the CMS BALANCE Model for GLP-1 obesity coverage in 2027?” If no, keep shopping.
For a full Medicare GLP-1 guide with Medicaid state-by-state coverage details, see our Medicare Wegovy coverage guide.
The fastest commercial path to Wegovy HD coverage
Ro does NOT coordinate GLP-1 coverage for Medicare, Medicaid, TRICARE, or VA plans.
If that’s where your coverage sits, jump back up to the Medicare section for the GLP-1 Bridge pathway that does fit your situation.
If you have commercial insurance or FEHB and want help handling the Wegovy HD PA, Ro’s insurance concierge is the cleanest next step on this query. Ro contacts your insurer directly via its free GLP-1 Insurance Coverage Checker, reports your Wegovy coverage status and PA requirements in a personalized email, and — for paying Ro Body members — submits the PA and resubmits after denials. If your plan denies Wegovy, Ro’s affiliated providers can assess whether you’re eligible for another FDA-approved GLP-1 and resubmit the authorization accordingly.
Ro does:
- \u2713Contact your insurer to confirm coverage
- \u2713Submit the PA and follow up with the insurer
- \u2713File appeals when denied
- \u2713Resubmit under a different GLP-1 if appropriate
- \u2713Match NovoCare and LillyDirect self-pay pricing
- \u2713Ship Wegovy direct when you’re paying cash
Ro does not:
- \u00d7Coordinate Medicare, Medicaid, TRICARE, or VA coverage
- \u00d7Include the medication cost in the membership fee
- \u00d7Handle government insurance PAs
Current Ro pricing
Ro Body membership: $39 first month, then $149/month ongoing, or as low as $74/month with an annual plan paid upfront. Medication cost is separate. If your plan covers Wegovy, your copay may be as low as $25/month with the Novo Nordisk commercial savings card. Verify at ro.co/weight-loss/pricing before committing.
“Initially, my insurance company covered Wegovy, and I was able to get a prescription and a prior authorization. During the Wegovy shortages, we waited — and waited — for it to come back in stock. While I was waiting, I saw that Ro had started offering Zepbound and contacted my team. They immediately switched my prescription to Zepbound… the team at Ro jumped into action and got the prior authorizations completed through my insurance… All of that happened within about a week of contacting Ro and asking about switching my prescription.”
— Ro Body member, quoted in Ro’s 2025 GLP-1 Coverage Checker Report
“Ro is more efficient, responsive and has competitive pricing even with the subscription requirement.”
— Trustpilot review of Ro
These are patient testimonials illustrating the administrative experience. Individual results vary.
Ro runs your specific insurance and emails you a personalized coverage report. Commercial and FEHB plans only.
Self-pay options if your plan still won’t cover Wegovy HD
If you’ve been through appeals and your plan still won’t cover Wegovy HD, you have three legitimate paths. The right answer depends on whether the blocker is clinical, administrative, or structural.
Option 1 — NovoCare Pharmacy self-pay
$399/month for Wegovy HD 7.2 mg
Novo Nordisk’s direct-to-patient pharmacy sells Wegovy HD for $399/month (vs. $349/month for Wegovy 2.4 mg and $149/month for Wegovy pill starter doses). List price is $1,349.02 per monthly package. No insurance, no PA, ships direct to your door. Verify current pricing and promotional terms on the NovoCare page before ordering — Novo Nordisk modifies offers periodically.
Option 2 — Stay on Wegovy 2.4 mg and wait for coverage to catch up
If 2.4 mg is still producing weight loss, there’s no urgency to switch. Wegovy HD is specifically indicated for patients who’ve tolerated 2.4 mg and need additional weight reduction. If you’re still losing weight at 2.4 mg — or within reach of your target — staying put until your plan catches up is reasonable. The $50/month price difference (NovoCare: $349 for 2.4 mg vs. $399 for HD) is another reason patients often wait for coverage rather than paying cash for the higher dose.
Option 3 — Sesame Care for branded self-pay
Sesame Care offers direct self-pay access to Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, and Saxenda with no ongoing membership fee for the marketplace itself. Costco members have historically found favorable Wegovy pricing on Sesame. This is a different value proposition from Ro: no concierge, no PA submission, just direct pricing on branded medications. Better for patients who already have a prescription and just want the cheapest fill.
Check Wegovy pricing on Sesame Care →| Dose | NovoCare self-pay/month | With commercial insurance + savings card | Medicare Bridge (July 1–Dec 31) |
|---|---|---|---|
| Wegovy pill 3 mg (starter) | $149 | As low as $25/mo | Included |
| Wegovy 2.4 mg injection | $349 | As low as $25/mo | Included |
| Wegovy HD 7.2 mg injection | $399 | As low as $25/mo | $50/mo |
Novo Nordisk commercial savings card: eligible commercially insured members may pay as little as $25/month, maximum savings $100/month. Medicare, Medicaid, TRICARE, VA members ineligible for the savings card. Verify at wegovy.com.
For a full comparison of Wegovy costs across providers, see our cheapest Wegovy without insurance guide.
Wegovy HD prior authorization FAQ
- Does Wegovy HD require a new prior authorization if my regular Wegovy was already approved?
- Usually yes. Most plans treat Wegovy HD as either a new-drug PA or a dose-escalation PA, both of which require a separate submission from your original Wegovy approval. A dose-escalation PA typically requires less documentation than a first-time Wegovy approval. The FDA label also requires documented tolerance of Wegovy 2.4 mg for at least 4 weeks before HD can be prescribed.
- Why does my plan say Wegovy is covered but the pharmacy says Wegovy HD is not?
- Because Wegovy HD has its own National Drug Code (0169-4572-14) distinct from Wegovy 2.4 mg, and your plan's pharmacy benefit system may not have loaded the HD NDC yet even though the 2.4 mg is active. This isn't a denial — it's an operational lag. Ask your pharmacy to contact the plan's pharmacy help desk with the HD NDC; this is typically an operational update, not an appeal.
- How much does Wegovy HD cost without insurance?
- Through NovoCare Pharmacy self-pay, Wegovy HD is $399 per month. The list price is $1,349.02 per monthly package. Through Ro's cash-pay program, Wegovy branded pricing matches NovoCare. Verify current pricing before purchasing.
- Does Medicare cover Wegovy HD in 2026?
- Standard Medicare Part D does not cover Wegovy for weight loss. From July 1 through December 31, 2026, the Medicare GLP-1 Bridge covers Wegovy (including HD, NDC 0169-4572-14) for eligible Part D beneficiaries at $50/month. Medicare Part D can also cover Wegovy 2.4 mg for cardiovascular risk reduction in adults with established cardiovascular disease who meet the CV criteria. Wegovy HD specifically is not labeled for the CV indication.
- What do I do if my Wegovy HD prior authorization is denied?
- Get the denial reason in writing. If the problem is operational or documentation, resubmit with a complete packet. If the denial is clinical or categorical, file an internal appeal — for most non-grandfathered plans under federal rules, generally within 180 days of the denial notice. Request a peer-to-peer review if the first appeal is denied. If internal appeal fails, request external independent review, generally within 4 months of the final internal denial.
- Does Ro handle Wegovy HD prior authorization?
- Yes, for commercial insurance and FEHB members. Ro's insurance concierge submits the PA, follows up with the insurer, and appeals denials. Ro does not coordinate GLP-1 coverage for Medicare, Medicaid, TRICARE, or VA plans. Ro Body membership is $39 first month, then $149/month (or as low as $74/month with annual prepay). Medication cost is separate.
- How long does Wegovy HD prior authorization take?
- Decision timelines vary by insurer, state, and whether the request is urgent or standard. Ask your plan directly for its standard and urgent decision timeframes. Medicare GLP-1 Bridge PAs beginning July 1, 2026 will run through a central processor, not your Part D plan — timing for that pathway is being finalized by CMS in Spring 2026.
- What BMI do I need for Wegovy HD coverage?
- Most commercial plans require a BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The Medicare GLP-1 Bridge criteria are BMI ≥35 alone; or BMI ≥30 with HFpEF, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD.
- Do I need to try other weight-loss medications before Wegovy HD?
- It depends on your plan. CVS Caremark does not require step therapy for Wegovy — it’s the preferred GLP-1 on their largest commercial formularies as of July 2025. Most other commercial plans require a 3-month trial of at least one lower-cost anti-obesity medication (orlistat, phentermine, Contrave, or Qsymia) before approving Wegovy, unless you document contraindications or prior failures. Prior Ozempic use often counts toward step therapy.
- What does “tolerated Wegovy 2.4 mg for at least 4 weeks” mean?
- Your medical record must show at least 4 consecutive weekly doses of Wegovy 2.4 mg without serious adverse reactions that led to discontinuation or dose reduction. Mild GI symptoms that resolved are fine. It means you were actually on the 2.4 mg dose — not a lower titration dose — for that 4-week window.
- Can the Novo Nordisk savings card be used with Wegovy HD?
- Yes, if you have commercial (non-government) insurance. Eligible patients may pay as little as $25 per month, with a maximum savings of $100 per month. Government beneficiaries (Medicare, Medicaid, TRICARE, VA) are excluded. Enroll at wegovy.com.
- Does Medicaid cover Wegovy HD?
- Medicaid weight-loss GLP-1 coverage varies by state and is changing rapidly. Oregon’s public drug list already includes Wegovy HD as pharmacy-PA. Check your state’s current preferred drug list.
- What if my employer plan excludes weight-loss drugs entirely?
- A cleaner PA packet won’t fix a benefit exclusion. Your three real paths are: (1) The CV lane — if you have established cardiovascular disease, Wegovy 2.4 mg has a separate CV indication many plans cover even when weight-loss drugs are excluded; (2) Employer benefits escalation — Novo Nordisk provides a free letter template to submit to your HR or benefits manager; (3) Self-pay fallback — NovoCare Pharmacy self-pay is $399/month for Wegovy HD.
How we built and verified this guide
This guide is assembled from primary sources — the FDA-approved Wegovy prescribing information, Novo Nordisk’s provider and patient materials, major payers’ published 2026 PA policies, the CMS Medicare GLP-1 Bridge program documents, and Ro’s current public pricing and insurance pages. Every factual claim links to the underlying source or is flagged as editorial inference. Where a payer has not yet published a Wegovy HD-specific policy, we say so and describe what the existing Wegovy 2.4 mg policy plus the FDA label’s HD-specific requirements would likely produce.
What can change fast:
- •NovoCare self-pay pricing and promotional terms
- •PBM formulary placements and preferred-status decisions
- •State Medicaid coverage policies
- •CMS Medicare GLP-1 Bridge operational details
- •Ro’s pricing, membership terms, and government-insurance handling
We re-verify this page monthly. The last-verified date above is our commitment that we checked the sources on that date.
Not sure which path fits your situation?
Take our free 60-second GLP-1 matching quiz. We’ll factor in your coverage, budget, and goals and return a personalized action plan — which provider to use, what your PA criteria look like, and what you’ll actually pay.
Get my personalized Wegovy HD action plan →Related guides on The RX Index
- Wegovy HD vs Wegovy 2.4 mg: What’s Different? →
- Wegovy HD Reviews: What Patients Report →
- How to Get Wegovy HD Online →
- Best Telehealth Services for Wegovy (2026) →
- Blue Cross Wegovy Prior Authorization (2026) →
- Does Insurance Cover Wegovy for Weight Loss? →
- How to Appeal a Wegovy Denial →
- GLP-1 Letter of Medical Necessity Guide →
- The Medicare GLP-1 Bridge Program Explained →
- Does Medicare Cover Wegovy? (2026 Guide) →
- Wegovy Savings Card: Eligibility and How It Works →
- Cheapest Wegovy Without Insurance (2026) →
By The RX Index Editorial Team. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Published April 21, 2026. Last verified: April 21, 2026. Next scheduled review: May 21, 2026.
Affiliate disclosure: The RX Index may earn a commission if you start a program through some of our links. This does not change your price, and it does not change which providers we recommend.
Medical disclaimer: This page is for educational purposes only and is not medical advice. A licensed prescriber makes all final eligibility and treatment decisions. Compounded semaglutide is not Wegovy HD and cannot be substituted for it legally or clinically.